L-serine

Phase 3Small molecule

PPhoenix Neurological Associates, LTD

L-serine is one of 3 small molecule programs targeting Macular Telangiectasia Type 2. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular Telangiectasia Type 2Not yet recruiting

Macular Telangiectasia Type 2Phase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Macular Telangiectasia Type 2

#DrugCompanyPhaseTrials

Tricor

JJagotec

Approved

—2

L-serine

PPhoenix Neurological Associates, LTD

Phase 3

6 3

Zeaxanthin

PPaul S. Bernstein

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Not yet recruiting

Study completion

NCT07342439

Clinical

Trials by Indication[1]

Neuropathy2 trials

Hereditary Sensory Neuropathy Serine Trial

Unknown status·UUniversity College, London·Phase 2·NCT06113055·50 enrolled

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Completed·MMassachusetts General Hospital·Phase 1/2·NCT01733407·18 enrolled

ALS1 trial

Determining the Safety of L-serine in ALS

Unknown status·PPhoenix Neurological Associates, LTD·Phase 1/2·NCT01835782·20 enrolled

Amyotrophic Lateral Sclerosis1 trial

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated·UUnknown Sponsor·Phase 2·NCT03580616·43 enrolled

Phase II1 trial

Phase IIa L-serine Trial for eAD

Terminated·AAleksandra Stark·Phase 2·NCT03062449·29 enrolled

Unspecified1 trial

Study of Serine Supplementation to Protect Vision in MacTel

Not yet recruiting·—·Phase 3·NCT07342439·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for L-serine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-serine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-serine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phoenix Neurological Associates, LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPhoenix Neurological Associates, LTD

L-serine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Neuropathy2 trials

ALS1 trial

Amyotrophic Lateral Sclerosis1 trial

Phase II1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News